Aynacioglu A S, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schröder T, Kayaalp S O, Roots I, Brockmöller J
Institute of Clinical Pharmacology, University Clinic Charité, Humboldt University, Berlin, Germany.
Clin Pharmacol Ther. 1999 Aug;66(2):185-92. doi: 10.1053/cp.1999.v66.100072001.
The genetically polymorphic cytochrome P450 enzymes 2Cl9 (CYP2Cl9) and 2D6 (CYP2D6) contribute to the metabolism of about 30% of all drugs. For analysis of the ethnic-related differences in drug disposition and as a preparation for routine genotyping, we examined CYP2C19 and CYP2D6 mutations in a large Turkish population.
CYP2C19 and CYP2D6 alleles were determined with use of genomic deoxyribonucleic acid from 404 unrelated Turkish individuals. CYP2C19 alleles *1 to *5 and CYP2D6 alleles *1 to *12, and *14, *15, and *17 were measured by polymerase chain reaction-restriction fragment length polymorphism assays.
From 404 subjects genotyped for CYP2C19, allele frequencies of CYP2C191 (wt), CYP2C192 (ml), and CYP2C193 (m2) were 0.88, 0.12, and 0.004, respectively; mutations m3 and m4 were not found. Four individuals (1.0%) were predicted to be poor metabolizers (CYP2C192/2), a significantly lower frequency compared to Middle European populations. Among 404 subjects genotyped for CYP2D6, most frequent alleles were CYP2D61 (allele frequency 0.37), *2 (0.35), *4 (0.11), *10 (0.06), duplications *1x2, *2x2, or *4x2 (0.06), *5 (0.01), and *17(0.01). Overall, six subjects (1.49%) were predicted to be CYP2D6 poor metabolizers, and 35 subjects (8.66%) were predicted to be ultrarapid metabolizers as a result of CYP2D6 gene duplications.
Obviously, within Europe there is a north-south gradient, with decreasing frequency of poor metabolizers of CYP2C19 and CYP2D6 to the south and a corresponding increase of ultrarapid metabolizers of CYP2D6. As in other white groups, only CYP2C19*2 plays a relevant role for the CYP2C19 poor metabolizer phenotype. The mutational spectrum of CYP2D6 indicated partial ethnic relationships to Asian and African populations.
基因多态性细胞色素P450酶2C19(CYP2C19)和2D6(CYP2D6)参与了约30%的药物代谢。为分析药物处置方面的种族差异并为常规基因分型做准备,我们在一大群土耳其人群中检测了CYP2C19和CYP2D6突变。
使用来自404名不相关土耳其个体的基因组脱氧核糖核酸测定CYP2C19和CYP2D6等位基因。通过聚合酶链反应-限制性片段长度多态性分析检测CYP2C19等位基因1至5以及CYP2D6等位基因1至12、*14、15和17。
在404名进行CYP2C19基因分型的受试者中,CYP2C191(野生型)、CYP2C192(m1)和CYP2C193(m2)的等位基因频率分别为0.88、0.12和0.004;未发现m3和m4突变。4名个体(1.0%)被预测为慢代谢者(CYP2C192/2),与中欧人群相比频率显著更低。在404名进行CYP2D6基因分型的受试者中,最常见的等位基因是CYP2D61(等位基因频率0.37)、*2(0.35)、*4(0.11)、10(0.06)、重复型1x2、2x2或4x2(0.06)、5(0.01)和17(0.01)。总体而言,6名受试者(1.49%)被预测为CYP2D6慢代谢者,35名受试者(8.66%)由于CYP2D6基因重复被预测为超快代谢者。
显然,在欧洲存在南北梯度差异,CYP2C19和CYP2D6慢代谢者的频率向南降低,而CYP2D6超快代谢者相应增加。与其他白种人群一样,只有CYP2C19*2对CYP2C19慢代谢者表型起相关作用。CYP2D6的突变谱表明与亚洲和非洲人群存在部分种族关联。